Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Equity Income: 2024-2025

Historic Equity Income for Ani Pharmaceuticals (ANIP) over the last 2 years, with Sep 2025 value amounting to $3.1 million.

  • Ani Pharmaceuticals' Equity Income rose 131.73% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $560,000, marking a year-over-year change of. This contributed to the annual value of $6.3 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Equity Income is $3.1 million, which was up 845.78% from $332,000 recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Equity Income registered a high of $9.7 million during Q1 2024, and its lowest value of -$2.7 million during Q2 2024.
  • Moreover, its 2-year median value for Equity Income was $332,000 (2025), whereas its average is $1.3 million.
  • Within the past 5 years, the most significant YoY rise in Ani Pharmaceuticals' Equity Income was 131.73% (2025), while the steepest drop was 109.54% (2025).
  • Quarterly analysis of 2 years shows Ani Pharmaceuticals' Equity Income stood at -$2.0 million in 2024, then skyrocketed by 131.73% to $3.1 million in 2025.
  • Its Equity Income stands at $3.1 million for Q3 2025, versus $332,000 for Q2 2025 and -$921,000 for Q1 2025.